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ABSTRACT
The spectrum of activity and potency of doripenem, a broad-spectrum parenteral carbapenem
currently in clinical development, was evaluated using 16 008 clinical bacterial isolates collected as part
of an international surveillance project during 2003. Using reference broth microdilution methods,
doripenem was found to be highly active against oxacillin-susceptible Staphylococcus aureus and
coagulase-negative staphylococci (2705 and 297 isolates, respectively; MIC90s 0.06 mg ⁄L), with a
potency greater than that of other carbapenem antibiotics. Against enterococci (1474 isolates), with the
exception of Enterococcus faecium, doripenem displayed modest activity (MIC50 4). Doripenem was
among the most potent agents tested against Streptococcus pneumoniae, viridans group streptococci and
b-haemolytic streptococci (885, 140 and 397 isolates; MIC90s 0.5, 0.5 and 0.03 mg ⁄L, respectively). For
Enterobacteriaceae (> 6200 isolates), doripenem was four- to 32-fold more active than imipenem
against wild-type isolates (MIC90s 0.03–0.5 mg ⁄L). MIC90s for conﬁrmed extended-spectrum
b-lactamase-producing Escherichia coli and Klebsiella pneumoniae (121 and 155 isolates; 0.06 and
0.12 mg ⁄L, respectively) were two-fold higher than for wild-type isolates. Doripenem was also active
against Citrobacter spp., Enterobacter spp. and Serratia spp. (MIC90s 0.06–0.25 mg ⁄L), including
ceftazidime-resistant isolates. Doripenem and meropenem were the most active agents among all
b-lactams against Pseudomonas aeruginosa (829 isolates; MIC50 ⁄ 90s 0.5 ⁄ 8 and 0.5 ⁄ 16 mg ⁄L, respectively),
whereas doripenem and imipenem were the most active agents against Acinetobacter spp. (155 isolates;
MIC50 ⁄ 90s 0.5 ⁄ 4 and £ 0.5 ⁄ 2 mg ⁄L, respectively). Doripenem was slightly more potent (MIC50 2 mg ⁄L)
than ertapenem and imipenem (MIC50 4 mg ⁄L), and had a potency similar to that of meropenem
(MIC50 2 mg ⁄L), against Burkholderia cepacia (20 isolates). Both Haemophilus inﬂuenzae (1824 isolates)
and Moraxella catarrhalis (108 isolates), including b-lactamase-positive isolates, were susceptible to
doripenem (MIC90s 0.25 and 0.03 mg ⁄L, respectively). Doripenem displays the favourable character-
istics of other carbapenems, and appears to offer certain advantages in terms of potency, spectrum and
b-lactamase stability when compared with some carbapenems used currently to treat nosocomial
infections.
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INTRODUCTION
b-Lactams are among the most widely prescribed
antimicrobial agents in both the community and
hospital settings. Their use for over 60 years has,
however, resulted in a dramatic increase in the
selection of b-lactamase variants that now threat-
en the utility of the majority of this large drug
family. Enzymes have been described that have
potent hydrolytic activity against penicillins,
cephalosporins (including extended-spectrum
agents), cephamycins and b-lactam–inhibitor
combinations [1]. The development and approval
of carbapenems was a milestone in addressing
this situation, because of their broad spectrum of
activity against most Gram-positive and -negative
pathogens, and their enhanced stability to most
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Ambler class A, C and D b-lactamases [2]. These
agents have generally been reserved for the most
severe infections, or for infections caused by
organisms known to be resistant to other available
b-lactams, especially those with an extended spec-
trum of activity (third- and fourth-generation
cephalosporins).
Given the current emphasis on broad-spectrum
agents targeting Gram-positive organisms, there
is a paucity of agents in development that are
directed at Gram-negative infections and that
have the universal success and broad safety
proﬁles enjoyed by b-lactams. In the USA, imipe-
nem and meropenem are the only carbapenems
available that display a broad spectrum of activity
against the important Gram-positive bacteria,
Enterobacteriaceae, anaerobes and non-fermenta-
tive bacilli such as Pseudomonas aeruginosa and
Acinetobacter spp. [3].
Doripenem (formerly S-4661; Shionogi Co. Ltd,
Osaka, Japan) is a novel parenteral 1-b-methyl
carbapenem with a molecular structure that
confers b-lactamase stability and resistance to
inactivation by renal dehydropeptidases [4–7]. In-
vitro studies have documented those characteris-
tics that make doripenem unique, including a
spectrum and potency against Gram-positive
cocci which is most similar to that of imipenem,
and an activity against Gram-negative bacteria
which is most like that of meropenem (i.e., two-
to four-fold greater than that of imipenem) [8–
12]. A particular feature, attributed to the side
chain at position 2, is greater activity against non-
fermentative Gram-negative bacilli that are multi-
drug-resistant [13,14]. Unfortunately, none of the
carbapenems is stable to the L1 enzyme pro-
duced by Stenotrophomonas maltophilia. Doripe-
nem displays favourable pharmacokinetic,
pharmacodynamic and toxicological features,
similar to those of meropenem, and this promis-
ing compound is currently in phase 3 clinical
trials [15–17].
Previous in-vitro studies have focused on lim-
ited populations of targeted species, particularly
resistant subsets or isolates from speciﬁc anatom-
ical sites of infection, and have not presented a
large geographical sampling of contemporary iso-
lates [8–11,18]. The present report summarises
the results of testing doripenem and comparator
agents against 16 008 Gram-positive and Gram-
negative isolates collected as part of an interna-
tional surveillance programme during 2003.
MATERIALS AND METHODS
Bacterial isolates tested
Non-duplicate, consecutive clinical isolates were submitted
from more than 70 medical centres located in North America
(38.3% of isolates), South America (13.7%) and Europe (48.0%)
as part of the global surveillance programme for the year 2003.
The isolates were predominantly from patients with documen-
ted bloodstream (61.9%), respiratory tract (15.5%), skin and soft
tissue (7.1%) or urinary tract (9.6%) infections, and were of
either nosocomial or community-acquired origin. The distribu-
tion of species and number of isolates were as follows:
Enterobacteriaceae, 6240 isolates;P. aeruginosa, 829;Acinetobacter
spp., 155; Sten. maltophilia, 80; Burkholderia cepacia, 20;Aeromonas
spp., 44; Haemophilus inﬂuenzae, 1853; Moraxella catarrhalis, 108;
Staphylococcus spp., 3711; Enterococcus spp., 1474; streptococci,
1435 (four groups); and other Gram-positive bacteria, 59. All
isolates were included as submitted by the study participants
and, with the single exception of vancomycin-resistant entero-
cocci, were not enriched with resistant isolates. Participants
were asked to submit additional isolates of vancomycin-resist-
ant enterococci (142 isolates received) to better deﬁne the
resistance proﬁles that occur within this group. Species identi-
ﬁcations were performed by the submitting laboratories, with
conﬁrmation by the central coordinating laboratory (JMI Labor-
atories, North Liberty, IA, USA), using established biochemical
algorithms, including the Vitek microbial identiﬁcation system
(bioMe´rieux, Hazelwood, MO, USA).
Antimicrobial susceptibility testing
All isolates were tested by the NCCLS reference broth micro-
dilution method [19] in Mueller–Hinton broth (with the
addition of lysed horse blood 2–5% v ⁄v or Haemophilus Test
Medium for testing fastidious species) against a variety of
antimicrobial agents representing the most common classes
and examples of drugs used in the empirical or directed
treatment of the indicated pathogen. Dry-form microdilution
panels and broth reagents were purchased from Trek Diag-
nostics (Cleveland, OH, USA). Doripenem standard powder
was provided by Peninsula Pharmaceuticals (New Brunswick,
NJ, USA); other agents were acquired from their respective
manufacturers or were purchased from Sigma Chemical Co.
(St Louis, MO, USA). Interpretation of quantitative MICs was
in accordance with NCCLS criteria [20]. Enterobacteriaceae
with elevated MICs (‡ 2 mg ⁄L) for ceftazidime and ⁄or ceftri-
axone and ⁄ or aztreonam were considered to have extended-
spectrum b-lactamase (ESBL)-producing phenotypes according
to NCCLS criteria [20]. ESBL conﬁrmation was by the disk
approximation method, incorporating testing with andwithout
clavulanic acid. Quality control isolates included Escherichia coli
ATCC 25922 and ATCC 35218, P. aeruginosa ATCC 27853,
H. inﬂuenzae ATCC 49247. Staphylococcus aureus ATCC 29213,
Streptococcus pneumoniae ATCC 49619 and Enterococcus faecalis
ATCC 29212 [20].
RESULTS
Staphylococci, streptococci and enterococci
The activities of doripenem and ten comparison
agents against methicillin (oxacillin)-susceptible
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S. aureus and coagulase-negative staphylococci
are shown in Table 1. Doripenem was the most
potent agent for the dilution ranges utilised
compared with the other agents, including carb-
apenems, and was 32- to 64-fold more potent than
cefepime. Among the carbapenems tested,
doripenem (MIC90 0.06 mg ⁄L) was two-fold more
active than meropenem (MIC90 0.12 mg ⁄L) and
two- to eight-fold more active than ertapenem
(MIC90 0.25–0.5 mg ⁄L) against the staphylococci.
Results with isolates from different geographical
regions showed minimal differences, although
coagulase-negative staphylococci of Latin Ameri-
can origin tended to display greater resistance to
ertapenem, while North American isolates were
more resistant to levoﬂoxacin (data not shown).
As expected, all b-lactams displayed higher MIC
values for oxacillin-resistant staphylococci (oxa-
cillin-resistant staphylococci are considered resist-
ant to all b-lactams), as did levoﬂoxacin. Only
vancomycin remained active against all isolates.
Susceptibility testing results for Ent. faecalis and
non-faecium species revealed a small number of
isolates that were resistant to vancomycin (vanco-
mycin-resistant enterococci) and teicoplanin,
occurring most commonly among North Ameri-
can isolates (8.2% and 4.0%, respectively).
Doripenem was two-fold less active than imipe-
nem, but two-fold more potent than ertapenem or
meropenem, against these enterococci (Table 1).
Only 0.9% of Ent. faecalis isolates were found to be
ampicillin-resistant. One isolate from North
America was linezolid-resistant (MIC > 8 mg ⁄L)
because of a G2576U mutation, and the greatest
proportion (46.1%) of levoﬂoxacin-resistant iso-
lates was found on that continent. A majority
(70.6%) of Ent. faecium isolates demonstrated
resistance to vancomycin, because of the inclusion
of 142 additional resistant isolates in the study.
None of the carbapenems displayed signiﬁcant
activity (MIC90 ‡ 16 mg ⁄L) against this species,
regardless of vancomycin susceptibility patterns.
The most active antimicrobial agent among those
tested against Ent. faecium was linezolid (99.0%
susceptible).
The population of Strep. pneumoniae tested
included 32.1% of isolates that were non-suscept-
ible to penicillin, and 25.5% that were resistant to
erythromycin; the carbapenems and vancomycin
were the most active agents tested (MIC90s £
0.5 mg ⁄L). Resistance to some agents varied
signiﬁcantly according to geographical region,
Table 1. In-vitro activity of doripenem in comparison









Staphylococcus aureus, oxacillin-susceptible (2705)
Doripenem 0.06 0.06 £ 0.008–4 –a –
Ertapenem 0.12 0.25 £ 0.06 to > 8 > 99.9 0.0
Imipenem £ 0.5 £ 0.5 £ 0.5–4 100.0 0.0
Meropenem 0.12 0.12 0.016–4 100.0 0.0
Cefepime 2 4 £ 0.12 to > 16 99.0 0.5
Ceftriaxone 4 4 0.5 to > 32 98.9 0.3
Ceftazidime 8 16 £ 1 to > 16 89.2 1.2
Oxacillin 0.5 1 £ 0.06–2 100.0 0.0
Piperacillin–tazobactam 1 2 £ 0.12–64 99.8 0.2
Levoﬂoxacin 0.12 0.5 £ 0.03 to > 4 94.2 4.1
Vancomycin 1 1 £ 0.12–4 100.0 0.0
Coagulase-negative staphylococci,
oxacillin-susceptible (297)
Doripenem 0.03 0.06 £ 0.008–8 –a –
Ertapenem 0.25 0.5 £ 0.06 to > 8 99.3 0.3
Imipenem £ 0.5 £ 0.5 £ 0.5–1 100.0 0.0
Meropenem 0.12 0.12 0.016–8 99.7 0.0
Cefepime 1 2 £ 0.12–8 100.0 0.0
Ceftriaxone 2 4 £ 0.25–32 98.3 0.0
Ceftazidime 4 8 £ 1 to > 16 96.3 0.7
Oxacillin 0.12 0.25 £ 0.06–0.25 100.0 0.0
Piperacillin–tazobactam 0.25 1 £ 0.12–4 100.0 0.0
Levoﬂoxacin 0.25 2 0.06 to > 4 90.9 5.1
Vancomycin 1 2 0.25–4 100.0 0.0
Enterococcus faecalis (1206) and
other non-faecium species (70)
Doripenem 4 8 £ 0.008 to > 16 –a –
Ertapenem 8 > 8 £ 0.06 to > 8 – –
Imipenem 1 4 £ 0.5 to > 8 – –
Meropenem 8 16 £ 0.008 to > 16 – –
Ceftriaxone > 32 > 32 £ 0.25 to > 32 – –
Ampicillin 2 4 £ 1 to > 16 97.6 2.4
Piperacillin–tazobactam 4 16 £ 0.12 to > 256 –b –b
Levoﬂoxacin 1 > 4 0.12 to > 4 61.1 37.6
Vancomycin 1 2 0.25 to > 16 92.9 5.5
Teicoplanin £ 2 £ 2 £ 2 to > 16 96.5 3.1
Linezolid 2 2 0.25 to > 8 99.9 0.1c
Enterococcus faecium (198)
Doripenem > 16 > 16 0.03 to > 16 –a –
Ertapenem > 8 > 8 8 to > 8 – –
Imipenem > 8 > 8 1 to > 8 – –
Meropenem > 16 > 16 4 to > 16 – –
Ampicillin > 16 > 16 £ 1 to > 16 8.6 90.4
Ceftriaxone > 32 > 32 0.5 to > 32 – –
Piperacillin–tazobactam > 256 > 256 8 to > 256 –b –b
Levoﬂoxacin > 4 > 4 1 to > 4 7.1 87.3
Vancomycin > 16 > 16 0.5 to > 16 28.4 70.6
Teicoplanin > 16 > 16 £ 2 to > 16 34.0 57.4
Linezolid 2 2 1–8 99.0 1.0
Streptococcus pneumoniae (885)
Doripenem 0.016 0.5 £ 0.008–1 –a –
Ertapenem £ 0.06 0.5 £ 0.06 to > 8 –d –d
Imipenem £ 0.5 £ 0.5 £ 0.5–1 –d –d
Meropenem 0.016 0.5 £ 0.008–2 –d –d
Cefepime £ 0.12 1 £ 0.12–4 94.9e 0.5e
Ceftriaxone £ 0.25 1 £ 0.25–8 97.5e 0.8e
Penicillin £ 0.03 2 £ 0.03 to > 4 67.9 16.1
Piperacillin–tazobactam £ 0.12 4 £ 0.12–16 – –
Levoﬂoxacin 1 2 0.06 to > 4 99.9 0.1
Vancomycin 0.25 0.5 £ 0.06–1 100.0 –
Erythromycin £ 0.25 16 £ 0.25 to > 32 73.8 25.5
Viridans group streptococcif (140)
Doripenem 0.03 0.5 £ 0.008 to > 16 –a –
Ertapenem 0.12 1 £ 0.06–4 – –
Imipenem £ 0.5 £ 0.5 £ 0.5–4 – –
Meropenem 0.06 0.5 £ 0.008 to > 16 90.7 –
Cefepime 0.25 1 £ 0.12–8 90.7 1.4
Ceftriaxone £ 0.25 1 £ 0.25–8 90.7 2.9
Penicillin 0.06 2 £ 0.016–32 65.7 7.9
Piperacillin–tazobactam 0.25 4 £ 0.12 to > 256 – –
Levoﬂoxacin 1 2 0.06 to > 4 99.3 0.7
Vancomycin 0.5 1 £ 0.12–2 99.3 –
Erythromycin £ 0.06 4 £ 0.06 to > 8 55.0 40.0
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with penicillin and erythromycin resistance vary-
ing from 14.1% and 15.1% in Latin America to
19.9% and 31.2%, respectively, in North America
(data not shown). All isolates (100%) and 99.9%
of isolates were susceptible to vancomycin and
levoﬂoxacin, respectively.
Against viridans group streptococci, doripe-
nem (MIC50 0.03 mg ⁄L) was two-fold more act-
ive than meropenem, and four-fold more active
than ertapenem (Table 1). There were 7.9%
penicillin-resistant isolates, with smaller percent-
ages also being resistant to ceftriaxone (2.9%)
and cefepime (1.4%). Penicillin resistance was
greatest in Latin America (23.1%) and least in
Europe (6.0%), whereas erythromycin resistance
was greatest in Europe (44.8%) and least in
Latin America (23.1%; data not shown). Strepto-
coccus bovis (13 isolates) had an antibiogram
most similar to that of viridans group strepto-
cocci, although the carbapenems, particularly
doripenem and meropenem, displayed greater
potency (MIC for all strains £ 0.016 mg ⁄L). The
Strep. bovis isolates were also susceptible to
penicillin.
Doripenem exhibited activity (MIC50 £
0.008 mg ⁄L) equal to or greater to that of penicil-
lin and the other carbapenems for the dilution
ranges tested against b-haemolytic streptococci
(groups A, B, C, F and G). All agents with
established breakpoints displayed > 99% sus-
ceptibility rates, with ertapenem, meropenem,
levoﬂoxacin and vancomycin showing 100% sus-
ceptibility.
Other Gram-positive species
Doripenem was slightly less active against Micro-
coccus spp. (13 isolates) than against staphylococci
(MIC50 ⁄ 90s 0.06 and 0.12 mg ⁄L, respectively), and
was similar in potency to meropenem. Only
vancomycin among the selected agents was uni-
formly active in vitro against Corynebacterium spp.
(17 isolates; MIC range 0.25–1 mg ⁄L); all carbap-
enems had high MIC90 values (‡ 16 mg ⁄L). Bacil-
lus spp. (12 isolates) were more susceptible to
doripenem (MIC50 ⁄ 90 0.06 ⁄ 4 mg ⁄L), which was
two- to four-fold more potent than the other
carbapenems. Only levoﬂoxacin and vancomycin
among selected comparators were consistently
more active. Doripenem and meropenem were
equally active (MIC50 ⁄ 90s 0.12 and 0.25 mg ⁄L)
against Listeria spp. (17 isolates), and were more
active than penicillin, levoﬂoxacin and vancomy-
cin (MIC90s 0.5, 1 and 1 mg ⁄L, respectively).
Enterobacteriaceae
The spectrum and activity of doripenem and
comparator agents against Enterobacteriaceae are
listed in Table 2. Almost 50% of the E. coli isolates
were ampicillin-resistant, and c. 13% were resist-
ant to levoﬂoxacin (10.2% in North America,
22.6% in Latin America, and 11.9% in Europe).
However, > 99.9% of isolates remained suscept-
ible to the carbapenems. Isolates from Europe had
a similar antibiogram to those from the USA,
whereas those from Latin America were more
resistant to ampicillin, third-generation cephalo-
sporins and ﬂuoroquinolones (data not shown). In
total, 121 isolates of E. coli were conﬁrmed as
ESBL producers by the clavulanate inhibition test
(4.0% of the total E. coli collection tested). The
prevalence of ESBL-producing E. coli in North
America, Latin America and Europe was 1.5%,
8.9% and 4.6%, respectively. Potencies of all
selected agents, including ﬂuoroquinolones, were
decreased markedly among ESBL producers, with
the exception of the carbapenems. Doripenem
displayed a potency against the ESBL producers
(MIC90 0.06 mg ⁄L) that was one dilution higher
than that against the wild-type population
(MIC90 0.03 mg ⁄L).
Against Klebsiella spp., the potency of doripe-
nem was comparable to that of meropenem and
the other carbapenems, given the dilution sched-










Doripenem £ 0.008 0.03 £ 0.008–0.25 –a –
Ertapenem £ 0.06 £ 0.06 £ 0.06–1 100.0 –
Imipenem £ 0.5 £ 0.5 £ 0.5–1 – –
Meropenem £ 0.008 0.06 £ 0.008–0.5 100.0 –
Cefepime £ 0.12 £ 0.12 £ 0.12–16 99.5 –
Ceftriaxone £ 0.25 £ 0.25 £ 0.25–16 99.2 –
Penicillin £ 0.016 0.06 £ 0.016–1 99.7 –
Piperacillin–tazobactam £ 0.12 0.5 £ 0.12–4 – –
Levoﬂoxacin 0.5 1 £ 0.03–2 100.0 0.0
Vancomycin 0.25 0.5 £ 0.12–1 100.0 0.0
aNo breakpoints have been established by the NCCLS [20].
bSusceptibility is predicted by the ampicillin result [20].
cOne strain with G2576U mutation.
dNon-meningitis breakpoints are not established [20].
eBased upon non-meningitis breakpoints [20].
fIncludes Strep. mitis (33 isolates), Strep. anginosus (14), Strep. sanguis (10), Strep. oralis
(nine), Strep. constellatus (eight), Strep. milleri (seven), Strep. salivarius (seven) and
others (52).
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susceptible. Geographical differences in the
Klebsiella spp. antibiogram (decreased activity
against third-generation cephalosporins) were
caused primarily by the presence of conﬁrmed
ESBL-producing isolates, which comprised 14%
of isolates overall, and which were most preval-
Table 2. In-vitro activity of doripenem in comparison
with selected antimicrobial agents against contemporary









Doripenem 0.03 0.03 £ 0.008–1 –a –
Ertapenem £ 0.06 £ 0.06 £ 0.06–4 99.9 0.0
Imipenem £ 0.5 £ 0.5 £ 0.5 to > 8 > 99.9 < 0.1
Meropenem 0.016 0.03 £ 0.008–2 100.0 0.0
Cefepime £ 0.12 £ 0.12 £ 0.12 to > 16 97.6 2.0
Ceftriaxone £ 0.25 £ 0.25 £ 0.25 to > 32 96.5 3.0 (4.5)b
Ceftazidime £ 1 £ 1 £ 1 to > 16 97.2 1.7 (5.1)b
Ampicillin 8 > 16 £ 1 to > 16 50.2 48.6
Ampicillin–sulbactam 4 > 32 £ 0.25 to > 32 56.4 25.3
Piperacillin–tazobactam 2 4 £ 0.12 to > 256 97.3 1.4
Levoﬂoxacin £ 0.03 > 4 £ 0.03 to > 4 85.6 12.6
E. coli (ESBL-conﬁrmed; 121)
Doripenem 0.03 0.06 0.016–1 –a –
Ertapenem £ 0.06 0.25 £ 0.06–4 99.1 0.0
Imipenem £ 0.5 £ 0.5 £ 0.5 100.0 0.0
Meropenem 0.03 0.06 0.016–2 100.0 0.0
Cefepime 16 > 16 £ 0.12 to > 16 43.0 47.9
Ceftriaxone > 32 > 32 £ 0.25 to > 32 24.8 70.2
Ceftazidime 16 > 16 £ 1 to > 16 47.1 32.2
Ampicillin > 16 > 16 16 to > 16 0.0 99.2
Ampicillin–sulbactam 32 > 32 2 to > 32 4.1 88.4
Piperacillin–tazobactam 8 128 0.5 to > 256 80.2 13.2
Levoﬂoxacin > 4 > 4 £ 0.03 to > 4 34.7 61.2
Klebsiella spp. (1107)
Doripenem 0.03 0.06 0.016 to > 16 –a –
Ertapenem £ 0.06 £ 0.06 £ 0.06 to > 8 98.8 0.8
Imipenem £ 0.5 £ 0.5 £ 0.5 to > 8 99.7 0.3
Meropenem 0.03 0.03 £ 0.008 to > 16 99.6 0.2
Cefepime £ 0.12 4 £ 0.12 to > 16 92.3 6.1
Ceftriaxone £ 0.25 32 £ 0.25 to > 32 85.5 9.8 (16.9)b
Ceftazidime £ 1 16 £ 1–16 89.3 8.6 (15.9)b
Ampicillin > 16 > 16 £ 1 to > 16 5.6 78.0
Ampicillin–sulbactam 8 > 32 £ 0.25 to > 32 70.5 22.4
Piperacillin–tazobactam 2 32 £ 0.12 to > 256 88.2 8.6
Levoﬂoxacin 0.06 2 £ 0.03 to > 4 90.8 7.1
Klebsiella spp. (ESBL-conﬁrmed; 155)
Doripenem 0.06 0.12 0.016–8 –a –
Ertapenem £ 0.06 0.5 £ 0.06 to > 8 97.9 1.4
Imipenem £ 0.5 £ 0.5 £ 0.5–2 100.0 0.0
Meropenem 0.03 0.12 0.016–2 100.0 0.0
Cefepime 8 > 16 £ 0.12 to > 16 54.2 35.5
Ceftriaxone > 32 > 32 £ 0.25 to > 32 11.6 60.6
Ceftazidime > 16 > 16 £ 1 to > 16 36.8 51.6
Ampicillin > 16 > 16 > 16 0.0 100.0
Ampicillin–sulbactam > 32 > 32 0.5 to > 32 5.2 85.8
Piperacillin–tazobactam 8 > 256 0.25 to > 256 60.0 31.0
Levoﬂoxacin 0.5 > 4 £ 0.03 to > 4 65.2 28.4
Enterobacter spp. (601)
Doripenem 0.06 0.12 £ 0.008–4 –a –
Ertapenem £ 0.06 1 £ 0.06 to > 8 96.8 1.3
Imipenem £ 0.5 1 £ 0.5 to > 8 99.7 0.2
Meropenem 0.03 0.12 £ 0.008–8 99.8 0.4
Cefepime £ 0.12 4 £ 0.12 to > 16 95.7 3.2
Ceftriaxone £ 0.25 > 32 £ 0.25 to > 32 77.5 14.7
Ceftazidime £ 1 > 16 £ 1 to > 16 76.0 20.5
Ampicillin > 16 > 16 2 to > 16 5.3 88.0
Ampicillin–sulbactam 32 > 32 1 to > 32 22.0 56.8
Piperacillin–tazobactam 2 64 £ 0.12 to > 256 81.4 8.7
Levoﬂoxacin 0.06 > 4 £ 0.03 to > 4 87.5 10.5
Citrobacter spp. (136)
Doripenem 0.03 0.06 £ 0.008–2 –a –
Ertapenem £ 0.06 0.12 £ 0.06–4 99.2 0.0
Imipenem £ 0.5 1 £ 0.5 to > 8 99.3 0.7
Meropenem 0.03 0.06 £ 0.008–4 100.0 0.0
Cefepime £ 0.12 1 £ 0.12 to > 16 97.8 2.2
Ceftriaxone £ 0.25 16 £ 0.25 to > 32 87.5 4.4
Ceftazidime £ 1 > 16 £ 1 to > 16 88.2 11.0
Ampicillin > 16 > 16 2 to > 16 10.3 77.2
Ampicillin–sulbactam 8 > 32 2 to > 32 64.0 23.5
Piperacillin–tazobactam 2 32 0.5 to > 256 88.2 4.4










Doripenem 0.12 0.25 0.016–0.5 –a –
Ertapenem £ 0.06 £ 0.06 £ 0.06–4 99.6 0.0
Imipenem 1 2 £ 0.5–8 99.7 0.0
Meropenem 0.06 0.06 0.016–1 100.0 0.0
Cefepime £ 0.12 £ 0.12 £ 0.12 to > 16 98.0 1.6
Ceftriaxone £ 0.25 £ 0.25 £ 0.25 to > 32 96.7 1.6
Ceftazidime £ 1 £ 1 £ 1 to > 16 98.4 0.7
Ampicillin 2 > 16 £ 1 to > 16 71.3 26.7
Ampicillin–sulbactam 1 32 0.5 to > 32 84.7 10.1
Piperacillin–tazobactam 0.25 1 £ 0.12–64 98.4 0.0
Levoﬂoxacin 0.06 > 4 £ 0.03 to > 4 86.0 10.1
Indole-positive Proteae (148)
Doripenem 0.12 0.5 0.03–1 –a –
Ertapenem £ 0.06 £ 0.06 £ 0.06–0.12 100.0 0.0
Imipenem 2 4 £ 0.5–4 100.0 0.0
Meropenem 0.06 0.12 0.016–0.5 100.0 0.0
Cefepime £ 0.12 0.25 £ 0.12 to > 16 99.3 0.7
Ceftriaxone £ 0.25 2 £ 0.25 to > 32 97.3 0.7
Ceftazidime £ 1 4 £ 1 to > 16 94.6 1.4
Ampicillin > 16 > 16 £ 1 to > 16 8.1 87.2
Ampicillin–sulbactam 16 32 0.5 to > 32 30.4 31.1
Piperacillin–tazobactam 0.5 4 £ 0.12–64 99.3 0.0
Levoﬂoxacin 0.06 4 £ 0.03 to > 4 86.5 9.5
Serratia spp. (187)
Doripenem 0.12 0.25 0.03–1 –a –
Ertapenem £ 0.06 0.12 £ 0.06–0.5 100.0 0.0
Imipenem £ 0.5 1 £ 0.5–8 99.5 0.0
Meropenem 0.03 0.06 0.016–0.25 100.0 0.0
Cefepime £ 0.12 0.5 £ 0.12 to > 16 95.7 4.3
Ceftriaxone £ 0.25 16 £ 0.25 to > 32 89.8 5.4
Ceftazidime £ 1 £ 1 £ 1 to > 16 94.6 3.8
Ampicillin > 16 > 16 4 to > 16 4.3 88.7
Ampicillin–sulbactam 32 > 32 4 to > 32 7.5 74.7
Piperacillin–tazobactam 2 32 0.5 to > 256 89.8 1.6
Levoﬂoxacin 0.12 1 £ 0.03 to > 4 93.5 3.8
Salmonella spp. (530)
Doripenem 0.06 0.06 0.016–0.25 –a –
Ertapenem £ 0.06 £ 0.06 £ 0.06–0.12 100.0 0.0
Imipenem £ 0.5 £ 0.5 £ 0.5–2 100.0 0.0
Meropenem 0.03 0.03 0.016–0.5 100.0 0.0
Cefepime £ 0.12 £ 0.12 £ 0.12 to > 16 97.4 0.6
Ceftriaxone £ 0.25 £ 0.25 £ 0.25 to > 32 96.6 3.0
Ceftazidime £ 1 £ 1 £ 1 to > 16 99.4 0.4
Ampicillin 2 > 16 £ 1 to > 16 75.8 23.4
Ampicillin–sulbactam 2 32 £ 0.25 to > 32 80.6 15.7
Piperacillin–tazobactam 4 4 0.5 to > 256 96.0 3.6
Levoﬂoxacin 0.06 0.25 £ 0.03–4 99.8 0.0
Shigella spp. (161)
Doripenem 0.03 0.06 0.016–0.06 –a –
Ertapenem £ 0.06 £ 0.06 £ 0.06 100.0 0.0
Imipenem £ 0.5 £ 0.5 £ 0.5 100.0 0.0
Meropenem 0.03 0.03 0.016–0.03 100.0 0.0
Cefepime 0.25 0.5 £ 0.12–1 100.0 0.0
Ceftriaxone £ 0.25 £ 0.25 £ 0.25–1 100.0 0.0
Ceftazidime £ 1 £ 1 £ 1 100.0 0.0
Ampicillin > 16 > 16 £ 1 to > 16 22.4 77.6
Ampicillin–sulbactam 32 32 1 to > 32 22.4 52.2
Piperacillin–tazobactam 2 4 0.25–8 100.0 0.0
Levoﬂoxacin £ 0.03 £ 0.03 £ 0.03–1 100.0 0.0
aNo breakpoints have been established by the NCCLS [20].
bPercentages in parentheses indicate those isolates meeting the NCCLS screening
criteria (MIC ‡ 2 mg ⁄L) for an ESBL-producing isolate [20].
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ent in Latin America (28.6%), followed by
Europe (15.6%) and North America (6.9%). The
doripenem MIC50 ⁄ 90s for ESBL-conﬁrmed isolates
were both only two-fold higher than those for the
entire population; however, the MIC90 of ertape-
nem was eight-fold higher, while that of
imipenem remained essentially unchanged. The
inhibitor combinations ampicillin–sulbactam and
piperacillin–tazobactam had markedly reduced
activity for the ESBL subset, as did levoﬂoxacin
(Table 2).
Enterobacter spp. were susceptible to carbapen-
ems, with doripenem and meropenem having
an identical MIC90 (0.12 mg ⁄L), making them
eight-fold more active than either ertapenem or
imipenem. Third- and fourth-generation cephalo-
sporins, piperacillin–tazobactam and levoﬂoxacin
all showed varying degrees of activity against
Enterobacter spp. (76.0–95.7% susceptibility). Like-
wise, doripenem and meropenem were the most
active compounds (MIC50 ⁄ 90s 0.03 ⁄ 0.06 mg ⁄L)
against Citrobacter spp. (136 isolates). Among
the carbapenems, imipenem was least active
(MIC90 1 mg ⁄L), although 99.3% of isolates
remained susceptible. Cefepime and levoﬂoxacin
were the next most active agents tested (97.8%
and 91.2% susceptible; Table 2).
The MIC90 of doripenem for Proteus mirabilis
was slightly higher than that of meropenem
(MIC90s 0.25 and 0.06 mg ⁄L, respectively); how-
ever, the highest doripenem MIC was only
0.5 mg ⁄L, compared with 1 mg ⁄L for merope-
nem. Ertapenem was slightly more active
(MIC90 £ 0.06 mg ⁄L), although the range extend-
ed to 4 mg ⁄L. Rates of resistance to ampicillin
(26.7%), ampicillin–sulbactam (10.1%) and levo-
ﬂoxacin (10.1%) were elevated. Piperacillin–tazo-
bactam was similar in activity to the carbapenems
(98.4% susceptible). The agents demonstrating
greatest activity against indole-positive Proteae
(four species), in decreasing order by MIC90s,
were: ertapenem (£ 0.06 mg ⁄L) > meropenem
(0.12 mg ⁄L) > cefepime (0.25 mg ⁄L) > doripenem
(0.5 mg ⁄L) > imipenem = ceftazidime = pipera-
cillin–tazobactam = levoﬂoxacin (4 mg ⁄L).
Against Serratia spp., doripenem, ertapenem
and meropenem were the most active agents
tested, with MIC90s of 0.25, 0.12 and 0.06 mg ⁄L,
respectively, and ‡ 99.5% susceptibility rates.
Cefepime, ceftazidime and levoﬂoxacin also dem-
onstrated > 90% susceptibility among the selected
comparators. Salmonella spp. were > 95% suscept-
ible to all selected agents, with the exceptions
of ampicillin (75.8%) and ampicillin–sulbactam
(80.6%). Most Shigella spp. were resistant to
ampicillin (77.6%) and ampicillin–sulbactam
(52.2%), but were otherwise susceptible to all
other selected agents. The highest doripenem
MIC for the Salmonella and Shigella spp. was
0.06 mg ⁄L (Table 2).
Non-fermentative Gram-negative bacilli and
Aeromonas spp.
Doripenem was the most active agent (MIC90 8
mg ⁄L) among the carbapenems against wild-
type P. aeruginosa (Table 3), being slightly
more potent than meropenem (MIC90 16 mg ⁄L),
imipenem and ertapenem (MIC90 > 8 mg ⁄L).
Resistance in P. aeruginosa to all tested carba-
penems was lowest in North America (2–6%),
intermediate in Europe (8–15%) and highest in
Latin America (10–21%), based upon proposed
tentative breakpoints for doripenem, which
are identical to those of other carbapenems
(Table 4). The greatest resistance to other agents
was observed for ceftriaxone (75.8%), levoﬂoxa-
cin (27.5%), aztreonam (21.7%), tobramycin
(21.5%), ceftazidime (19.2%) and piperacillin–
tazobactam (18.2%).
Imipenem was the most active carbapenem
(MIC50 ⁄ 90 £ 0.5 ⁄ 2 mg ⁄L) tested against Acineto-
bacter spp. (Table 3). Doripenem (MIC50 ⁄ 90
0.5 ⁄ 4 mg ⁄L) and meropenem (MIC50 ⁄ 90
1 ⁄ 8 mg ⁄L) were also active against these wild-
type isolates, whereas ertapenem displayed
marginal activity (MIC50 ⁄ 90 4 ⁄> 8 mg ⁄L). Among
other agents tested, tobramycin was the most
active compound (MIC50 1 mg ⁄L; 67.7% suscept-
ible), with cefepime (MIC50 8 mg ⁄L; 57.4%
susceptible), levoﬂoxacin (MIC50 0.5 mg ⁄L;
57.4% susceptible) and piperacillin–tazobactam
(MIC50 32 mg ⁄L; 49.7% susceptible) also retaining
some activity. As with P. aeruginosa, Latin Ameri-
can isolates of Acinetobacter spp. tended to display
much greater resistance to all drug classes, espe-
cially tobramycin (data not shown).
Among other Gram-negative bacilli investi-
gated, B. cepacia isolates were variable in
their patterns of susceptibility to carbapenems,
with meropenem being most active
(MIC50 ⁄ 90 2 ⁄ 4 mg ⁄L; 90.0% susceptible), followed
by doripenem (MIC50 ⁄ 90 2 ⁄ 8 mg ⁄L) and imipenem
(MIC50 ⁄ 90 4 ⁄ 8 mg ⁄L; 65.0% susceptible). Ceftazi-
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dime and cefepimewere also active (90% and 85%
of isolates susceptible), followed by piperacillin–
tazobactam and levoﬂoxacin (both showing 80%
susceptibility). Resistance was most pronounced
with tobramycin (75%), aztreonam (20%) and
ceftriaxone (20%). Sten. maltophilia isolates were
very resistant to the agents tested, particularly
carbapenems (83.5–98.7% resistant). Levoﬂoxacin
(87.5% susceptible) was the most active agent,
followed by ceftazidime (56.3%).
Aeromonas spp. were generally susceptible
(> 93.0%) to all agents tested, except for piperacil-
lin–tazobactam (60.5%). All carbapenems had
similar activity (MIC90 1–2 mg ⁄L) against Aero-
monas spp.
Fastidious respiratory tract pathogens
Meropenem was slightly more active than
doripenem (MIC50 ⁄ 90s 0.03 ⁄ 0.12 and 0.06 ⁄ 0.25
mg ⁄L, respectively) against H. inﬂuenzae (both
b-lactamase-positive and -negative phenotypes;
Table 5). The adverse effects of the TEM
enzyme in b-lactamase-positive isolates on the
activity of the carbapenems was minimal. The
b-lactamase-positive rate among H. inﬂuenzae
isolates was 21.8%, but the number of b-lacta-
mase-negative ampicillin-resistant isolates was
only 0.1% (Table 5). All other agents tested also
exhibited potent activity (> 94% susceptibility)
against H. inﬂuenzae, with the exceptions of
trimethoprim–sulphamethoxazole (75.6–83.5%)
and clarithromycin (80.9–86.7%). Against
M. catarrhalis, doripenem and the comparators
tested showed potent activity, with the expected
exception of penicillin. b-Lactamase production
was demonstrated for all but ﬁve (95.3%) of the
isolates with a chromogenic cephalosporin test.
Doripenem was more potent (MIC50 ⁄ 90 £
0.016 ⁄ 0.03 mg ⁄L) than the ﬂuoroquinolones
(ciproﬂoxacin and levoﬂoxacin), and showed
superior activity when compared with the
Table 3. In-vitro activity of doripenem in comparison
with selected antimicrobial agents against isolates of non-









Doripenem 0.5 8 0.03 to > 16 –a –
Ertapenem 8 > 8 0.12 to > 8 – –
Imipenem 1 > 8 £ 0.5 to > 8 80.7 13.5
Meropenem 0.5 16 0.016 to > 16 83.5 11.7
Cefepime 4 > 16 £ 0.12 to > 16 76.6 11.6
Ceftriaxone > 32 > 32 0.5 to > 32 7.2 75.8
Ceftazidime 4 > 16 £ 1 to > 16 75.0 19.2
Piperacillin–tazobactam 8 256 £ 0.12 to > 256 81.8 18.2
Aztreonam 8 > 16 0.25 to > 16 64.3 21.7
Levoﬂoxacin 0.5 > 4 0.06 to > 4 69.0 27.5
Tobramycin 0.5 > 16 £ 0.12 to > 16 77.3 21.5
Acinetobacter spp. (155)
Doripenem 0.5 4 0.016 to > 16 –a –
Ertapenem 4 > 8 £ 0.06 to > 8 – –
Imipenem £ 0.5 2 £ 0.5 to > 8 92.3 7.1
Meropenem 1 8 £ 0.016 to > 16 89.7 7.7
Cefepime 8 > 16 £ 0.12 to > 16 57.4 29.7
Ceftriaxone 32 > 32 £ 0.25 to > 32 31.0 40.6
Ceftazidime 8 > 16 £ 1 to > 16 52.3 37.1
Piperacillin–tazobactam 32 > 256 £ 0.12 to > 256 49.7 43.9
Aztreonam > 16 > 16 £ 0.12 to > 16 9.0 74.2
Levoﬂoxacin 0.5 > 4 £ 0.03 to > 4 57.4 38.1
Tobramycin 1 > 16 £ 0.12 to > 16 67.7 26.5
Burkholderia cepacia (20)
Doripenem 2 8 0.12 to > 16 –a –
Ertapenem 4 8 £ 0.06 to > 8 – –
Imipenem 4 8 £ 0.5 to > 8 65.0 10.0
Meropenem 2 4 0.06 to > 16 90.0 10.0
Cefepime 8 16 £ 0.12 to > 16 85.0 10.0
Ceftriaxone 16 > 32 £ 0.25 to > 32 35.0 20.0
Ceftazidime 4 4 £ 1 to > 16 90.0 10.0
Piperacillin–tazobactam 4 256 0.5 to > 256 80.0 15.0
Aztreonam 16 > 16 £ 0.12 to > 16 40.0 20.0
Levoﬂoxacin 1 4 £ 0.3 to > 4 80.0 10.0
Tobramycin > 16 > 16 £ 0.12 to > 16 15.0 75.0
Stenotrophomonas maltophilia (80)
Doripenem > 16 > 16 1 to > 16 –a –
Ertapenem > 8 > 8 1 to > 8 – –
Imipenem > 8 > 8 2 to > 8 1.3 98.7
Meropenem > 16 > 16 0.5 to > 16 5.1 83.5
Cefepime 16 > 16 1 to > 16 21.3 42.5
Ceftriaxone > 32 > 32 2 to > 32 2.5 91.2
Ceftazidime 8 > 16 £ 1 to > 16 56.3 35.0
Piperacillin–tazobactam 256 > 256 8 to > 256 5.0 56.2
Aztreonam > 16 > 16 4 to > 16 3.8 91.2
Levoﬂoxacin 1 4 0.12 to > 4 87.5 3.7
Tobramycin > 16 > 16 1 to > 16 11.3 72.5
Aeromonas spp. (44)
Doripenem 0.5 1 0.03–4 –a –
Ertapenem 0.25 1 £ 0.06 to > 8 – –
Imipenem £ 0.5 2 £ 0.5 to > 8 93.2 2.3
Meropenem 0.12 1 0.016–4 97.7 0.0
Cefepime £ 0.12 0.25 £ 0.12–4 100.0 0.0
Ceftriaxone £ 0.25 1 £ 0.25–32 97.7 0.0
Ceftazidime £ 1 £ 1 £ 1 to > 16 97.7 2.3
Piperacillin–tazobactam 8 128 1–256 60.5 11.6
Aztreonam £ 0.12 0.25 £ 0.12–2 100.0 0.0
Levoﬂoxacin £ 0.03 0.25 £ 0.03 to > 4 97.7 2.3
Tobramycin 1 4 0.25 to > 16 93.2 6.8
aNo breakpoints have been established by the NCCLS [20].
Table 4. Cumulative percentage of Pseudomonas aeruginosa




Cumulative % of isolates susceptible to each conc.
(mg ⁄L)
£ 0.5 1 2 4 8 ‡ 16
North America (226)
Doripenem 69 87 92 96 98 100
Meropenem 66 84 90 93 96 100
Imipenem 15 69 89 91 94 100
Europe (450)
Doripenem 53 73 79 86 92 100
Meropenem 54 68 75 83 88 100
Imipenem 11 59 74 80 85 100
Latin America (153)
Doripenem 44 59 65 76 90 100
Meropenem 42 56 63 71 79 100
Imipenem 11 51 65 67 79 100
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cephalosporins. Meropenem had the lowest
MIC50 ⁄ 90 (£ 0.008 mg ⁄L) against M. catarrhalis.
DISCUSSION
Doripenem is a novel broad-spectrum parenteral
carbapenem that is currently in the late stages of
clinical development in the USA. The microbio-
logical and pharmacokinetic ⁄pharmacodynamic
features of doripenem have been described pre-
viously [10,15,16], and clinical success in early
human trials has been reported from Japan
[21–23]. Several recent studies have shown that
doripenem incorporates the most favourable
characteristics of the carbapenem class of antimi-
crobial agents by combining the superior in-vitro
activities of imipenem against Gram-positive
cocci and of meropenem against Gram-negative
pathogens. In a study of drug-resistant pathogens,
doripenem retained the greatest potency among
carbapenems against ESBL- and AmpC-produc-
ing enteric bacilli, as well as against penicillin-
resistant Strep. pneumoniae [9]. Also, a greater
proportion of carbapenem-resistant P. aeruginosa
and Acinetobacter spp. isolates were inhibited by
doripenem at £ 4 mg ⁄L [7–9]. When compared
with several other anti-pseudomonal agents,
including other carbapenems, doripenem was
associated with the lowest rate of spontaneous
resistance [13].
The aim of the present study was to character-
ise the global antibiogram for doripenem and
other agents used in similar clinical circum-
stances. For a large (16 008 isolates) collection of
clinically signiﬁcant bacterial isolates collected in
2003, speciﬁc activity proﬁles demonstrated that
doripenem consistently displayed the greatest
potencies (MIC90s 0.03–0.5 mg ⁄L) against Gram-
positive pathogens, including oxacillin-suscept-
ible staphylococci, Strep. pneumoniae and
b-haemolytic and viridans group streptococci,
compared with other carbapenems and compara-
tor agents. Only oxacillin-resistant staphylococci
and enterococci (primarily Ent. faecium) had high-
er MICs, thereby compromising the usefulness of
doripenem against these organisms. Among
Enterobacteriaceae, the MIC50s and MIC90s
of doripenem were 0.03–0.12 mg ⁄L and 0.03–
0.5 mg ⁄L, respectively, and were similar to those
of meropenem (0.016–0.06 and 0.03–0.12 mg ⁄L),
whereas those of imipenem were higher (£ 0.5–
2 mg ⁄L and 0.5–4 mg ⁄L). Importantly, potencies
for all selected agents, with the exception of the
carbapenems (only two-fold increases in MIC90s),
were reduced markedly for conﬁrmed ESBL-
producing E. coli and Klebsiella spp., demonstra-
ting the inherent stability of the carbapenem class
against these enzymes. With the exception of Sten.
maltophilia, against which carbapenems are inac-
tive, doripenem retains the activity proﬁle of
meropenem against P. aeruginosa, and that of
imipenem against Acinetobacter spp., thereby pro-
viding evidence of enhanced stability to the
common resistance mechanisms found in these
species [13,14]. Doripenem was uniformly active
against the respiratory pathogens H. inﬂuenzae
and M. catarrhalis, with no MIC > 2 mg ⁄L.
Carbapenem agents were ﬁrst described in
1976, with the Food and Drug Administration
(FDA)-approved introductions of imipenem and
meropenem occurring in 1985 and 1996, respect-
Table 5. In-vitro activity of doripenem in comparison
with selected antimicrobial agents against isolates of










Doripenem 0.06 0.25 £ 0.008–2 –a –
Meropenem 0.03 0.12 £ 0.008–0.25 100.0 –
Cefepime £ 0.06 0.12 £ 0.06 to > 8 99.8 –
Ceftriaxone £ 0.008 0.016 £ 0.008 to > 16 99.9 –
Ampicillin £ 0.5 1 £ 0.5 to > 4 99.6 0.1
Ciproﬂoxacin £ 0.12 £ 0.12 £ 0.12 to > 16 99.9 –
Levoﬂoxacin £ 0.03 £ 0.03 £ 0.03–0.12 100.0 –
Trimethoprim–
sulphamethoxazole
£ 0.5 > 4 £ 0.5 to > 4 83.5 14.7
Clarithromycin 8 16 £ 0.25 to > 32 86.7 1.1
Tetracycline £ 2 £ 2 £ 2 to > 16 99.2 0.6
H. inﬂuenzae, b-lactamase-
positive (398)
Doripenem 0.12 0.25 £ 0.008–1 –a –
Meropenem 0.03 0.12 £ 0.008–0.25 100.0 –
Cefepime £ 0.06 0.12 £ 0.06–1 100.0 –
Ceftriaxone £ 0.008 £ 0.008 £ 0.008–2 100.0 –
Ampicillin > 4 > 4 1 to > 4 0.0 100.0
Ciproﬂoxacin £ 0.12 £ 0.12 £ 0.12 to > 16 99.7 –
Levoﬂoxacin £ 0.03 £ 0.03 £ 0.03–0.06 100.0 –
Trimethoprim–
sulphamethoxazole
£ 0.5 > 4 £ 0.5 to > 4 75.6 22.4
Clarithromycin 8 16 £ 0.25 to > 32 80.9 2.3
Tetracycline £ 2 £ 2 £ 2 to > 16 94.5 5.3
M. catarrhalis (108)
Doripenem 0.016 0.03 £ 0.008–0.5 –a –
Meropenem £ 0.008 £ 0.008 £ 0.008–0.12 – –
Cefepime 0.5 1 £ 0.06–4 – –
Ceftriaxone 0.12 0.5 £ 0.008–1 – –
Penicillin 4 > 4 £ 0.03 to > 4 – 95.3b
Ciproﬂoxacin £ 0.12 £ 0.12 £ 0.12–0.25 – –
Levoﬂoxacin £ 0.03 0.06 £ 0.03–0.12 – –
Trimethoprim–
sulphamethoxazole
£ 0.5 £ 0.5 £ 0.5–2 – –
Clarithromycin £ 0.25 £ 0.25 £ 0.25 – –
Tetracycline £ 2 £ 2 £ 2–16 – –
aNo breakpoints have been established by the NCCLS [20].
bPercentage of isolates that are b-lactamase-positive.
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ively. These events marked a milestone in the
treatment of infections caused by fermentative
and non-fermentative Gram-negative bacilli,
following the rise and dramatic increase in
organisms expressing b-lactamase enzymes (both
chromosomal and plasmid-mediated), which
rendered ineffective many of the penicillins and
cephalosporins (including extended-spectrum
agents) that remain in common usage [3].
As a class, carbapenems are innately stable to
most b-lactamases of Ambler classes A, C and D,
and are used widely for treating serious infections
involving resistant Enterobacteriaceae (including
ESBL-producing and AmpC-overproducing iso-
lates), anaerobes, P. aeruginosa and Acinetobacter
spp. Only recently have b-lactamases appeared
that are variably able to hydrolyse carbapenem
agents, including—most importantly—enzymes
in Ambler class B (metallo-b-lactamases (MBLs):
IMP, VIM, SPM, GIM series), and also class A
(SPE, NMC-A, IMI-1, KPC) and class D (OXA
series) enzymes [24–26]. Although the appearance
of these enzymes has limited the usefulness of
carbapenems in certain areas, serious problems
have been primarily clonal in nature, as focal
outbreaks, rather than being widespread in occur-
rence, as has been reported for other b-lactamases,
including ESBLs and cephalosporinases. How-
ever, this situation has been gradually changing
with the established presence of MBLs in areas
such as Japan, South America and Italy [27–29],
with 6.5% of all P. aeruginosa isolates found to
express MBLs in Italy [29,30]. Also, plasmid-
mediated mobilisation of the genes encoding
MBLs has resulted in their appearance in Entero-
bacteriaceae in a number of locations, thereby
complicating further the utilisation of carbapen-
ems [31–33].
These worrying developments highlight the
critical need for broad-spectrum agents that will
have a high probability of success with empirical
regimens, but occur at a time when pharmaceu-
tical development of agents targeting Gram-neg-
ative bacilli is extremely limited. Carbapenems
are assuming an ever greater role in institutions,
particularly with patient populations in whom
isolates with multidrug resistance to commonly
used antimicrobial agents currently exist or may
be expected to appear. Another worrying devel-
opment, conﬁrmed in the present study, is the
increasing number of Enterobacteriaceae with
resistance to widely prescribed agents, such as
levoﬂoxacin and ceftriaxone. The carbapenems
are unique among b-lactams in that they have
molecular characteristics that provide enhanced
stability to the most commonly occurring b-
lactamases. While sporadic resistance can emerge
following downregulation of outer-membrane
porins, increased expression of efﬂux pumps
and hyperproduction of cephalosporinases, it is
the genetic mobilisation of MBLs that gives
greatest cause for concern, given the high hydro-
lytic activity of these enzymes and their tendency
for rapid horizontal spread to other groups such
as the Enterobacteriaceae [13,14,25,33,34].
The in-vitro results in the present study
conﬁrm, among a very large global population
of contemporary clinical isolates, earlier reports
that doripenem has a very broad spectrum of
activity, with compromised activity limited to
the oxacillin-resistant staphylococci, Ent. faecium
and Sten. maltophilia. While activity was retained
against most P. aeruginosa, Acinetobacter spp. and
some B. cepacia isolates, and while carbapenems
remain among the most active agents, the
emergence of enzyme-mediated resistance
remains worrying and will only be addressed
speciﬁcally by the continued development of
new agents such as doripenem. The solution
involves educational efforts targeting prescri-
bing patterns, strict application of infection
control practices, and use of data from surveil-
lance programmes for tracking resistance phe-
notypes at the local, regional and national
levels.
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